Stock price when the opinion was issued
EPS of $0.3256 beat estimates of $0.3065 and revenues of $117.38M beat estimates of $113.08M. Management is overall pleased with its results given the decrease in call volume due to a declining death rate. It continues to gain market share and sales grew by 8.2%, driven mostly by acquired operations. PLC plans on divesting certain legacy assets to Everstory Acquisition Portfolio, a transaction valued at $70M. This divestiture is expected to reduce PLC's leverage ratio and provide cash for deployment into high-growth markets. Its balance sheet slightly expanded for the quarter, and sales grew, but its margins declined due to increasing interest expenses and cost of sales. It has made some progress on its debt load, but its net debt/EBITDA ratio remains high at 3.9X. We feel it is a well-run business, and in a better market backdrop it will perform well. Its high debt load is certainly acting as a drag on its financial performance, and we feel a recovery is likely once interest rates peak or decline.
Unlock Premium - Try 5i Free
Recession-proof with high barriers to entry. Great managers. Revenues surged from the higher death rates during Covid, and they entered the TSX. But the stock then plunged given rough YOY comps, investors got nervous over an acquisition, and they got kicked out of the TSX. Now, it trades cheaply at 8x EBITDA and are buying back shares. They just sold a lower-margin price at a good price, so margins will grow. Expect more acquisitions.
(Analysts’ price target is $23.75)
PLC reported revenue of $85.3 million, up 12.4% year-over-year, missing estimates of $86.5 million. Adjusted EBITDA of $18.8 million rose 21% year-over-year but missed estimates of $19.7 million. EBITDA margin rose from 20.6% in the second quarter of 2022 to 22.1% in the recent quarter. Adjusted earnings per share of $0.22 came in line with estimates and rose 16.8% year-over-year. Mortality rates in the US are declining, or more normalizing after the rates during the pandemic years. The second quarter cyclically is the weaker quarter for the company. A competitor revised down 2023 guidance by 3% for EPS citing lower pre-need cemetery sales and higher borrowing costs. We don't think this quarter had any major takeaways and continue liking the name for the long-term. We would be fine starting a position.
Unlock Premium - Try 5i Free